REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$781.49
arrow_downward
-1.48%(-11.77) 1D
$781.49
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 11, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$800.00
High
$800.22
Low
$780.81
Mkt. cap
80.46B
Avg. vol.
728.61K
Volume
443.99K
Dividend
0.48%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
19.32
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.20
Shares outstanding
101.14M
No. of employees
15K
Open
$800.00
High
$800.22
Low
$780.81
Mkt. cap
80.46B
Avg. vol.
728.61K
Volume
443.99K
Dividend
0.48%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
19.32
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.20
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
GlobeNewswire
·
5 hours ago
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc.
Kalkine Media
·
1 day ago
Is Regeneron (NASDAQ:REGN) Entering A New Phase?
TipRanks
·
1 day ago
Regeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside
Simply Wall Street
·
1 day ago
Why Is Regeneron Pharmaceuticals (REGN) Facing A New Investor Lawsuit?
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com